Hi docj, This only proves to me that CytoDyn is
Post# of 153834
(Total Views: 558)
Posted On: 01/05/2025 4:42:54 PM
Hi docj,
This only proves to me that CytoDyn is doing exactly what my Laying Low post requested which is to soften the impact of the presentation or to tone down the presentation.
My thoughts were that they would still present it given what was stated in the Letter to Shareholders December 2024 and then they did actually get approval to do the presentation, but despite this, they made the decision not to present.
Madrigal was the sponsor of the conference. Maybe once they learned that Madrigal was the sponsor, they decided against it?
Madrigal's drug Resmetirom is the only FDA approved med for MASH and CytoDyn's leronlimab was better in both the reduction of steatosis and fibrosis. It would have been an embarrassment because the reduction of fat and scar tissue is the name of the game in MASH and it is very hard to do, yet leronlimab does it.
CytoDyn can still get this fantastic news out and they will. Melissa Palmer might act in this regard and in a couple of weeks, the results of the 2nd preclinical murine study comes back confirming the reduction of fibrosis regardless of how it was formed.
Soon thereafter, CytoDyn becomes immersed in a Pulmonary Fibrosis Pilot Trial.
This only proves to me that CytoDyn is doing exactly what my Laying Low post requested which is to soften the impact of the presentation or to tone down the presentation.
My thoughts were that they would still present it given what was stated in the Letter to Shareholders December 2024 and then they did actually get approval to do the presentation, but despite this, they made the decision not to present.
Madrigal was the sponsor of the conference. Maybe once they learned that Madrigal was the sponsor, they decided against it?
Madrigal's drug Resmetirom is the only FDA approved med for MASH and CytoDyn's leronlimab was better in both the reduction of steatosis and fibrosis. It would have been an embarrassment because the reduction of fat and scar tissue is the name of the game in MASH and it is very hard to do, yet leronlimab does it.
CytoDyn can still get this fantastic news out and they will. Melissa Palmer might act in this regard and in a couple of weeks, the results of the 2nd preclinical murine study comes back confirming the reduction of fibrosis regardless of how it was formed.
Soon thereafter, CytoDyn becomes immersed in a Pulmonary Fibrosis Pilot Trial.
(4)
(0)